Navigation Links
AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
Date:5/13/2008

etrorelix

Cetrorelix is part of AEterna Zentaris' LHRH antagonist therapeutic approach that has demonstrated in Phase 2 studies to provide fast and long-lasting relief of BPH symptoms while being well tolerated, with a low incidence of sexual side effects. Cetrorelix peptide-based drugs were developed by the Company in cooperation with Nobel Prize winner Prof. Andrew Schally, currently of the U.S. Veterans Administration in Miami.

Cetrorelix acetate is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization programs (controlled ovarian stimulation/assisted reproductive technologies) in Europe, the U.S. and Japan. It was launched on the market through Serono (now Merck Serono) in the United States, Europe and in several other countries, as well as in Japan through Shionogi.

About the Cetrorelix Phase 3 Program in BPH

Cetrorelix pamoate is being studied in three Phase 3 trials which will include approximately 1,500 men with symptomatic BPH in the United States, Canada and Europe. One Phase 3 efficacy trial, primarily in the United States and Canada and with additional sites in Europe, involves approximately 600 patients (which are fully enrolled) and is being led by Herbert Lepor, M.D., Professor and Martin Spatz Chairman of Urology, New York University School of Medicine, New York. In the trial, patients enter a no-treatment run-in observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (I-PSS). Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label extension, patients will receive cetrorelix by IM injection at Week 52, 54, 78 and 80 will be followed up to Week 90.

A second, similarly designed ongoing multi-cent
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 PMG Research, Inc. ... Research is a network of sites that provide clinical research ... 2 million patient lives through its partnerships with large physician ... 11 hub site locations in the Southeastern United States and ... of the board will be held by: Dr. ...
(Date:11/26/2014)... Continuing its award-winning streak, Nerium International, the ... Awards for outstanding creative achievement by its marketing and ... the organization’s top honor, in the Branding category for ... April of this year. The event showcased top speakers ... was awarded a Gold MarCom Award in the Special ...
(Date:11/26/2014)... 26, 2014 SoundConnect , an ... proud to announce that Darren Suders has joined the ... Darren will drive the partner program through ... , Darren brings more than 10-years of ... roles in channel operations, from policy development, to partner ...
(Date:11/26/2014)... -- Bio-Techne Corporation (NASDAQ: TECH ) announced ... to serve in a newly created position of Senior ... will be responsible for managing the operations of Bio-Techne,s ... acquired in July 2014 and the recently acquired CyVek ... -based ProteinSimple develops and commercializes proprietary systems and consumables ...
Breaking Biology Technology:PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2SoundConnect Appoints Director of Channel Development & Sales 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... be participating in the Barclays Capital 2010 Global Healthcare Conference in Miami, Fla. , on March 23, 2010 , at 8:30 a.m. Eastern Time .   , ... , ... ... ...
... for life science researchers, has selected Biodiagnostics as its new distributor of IPA® in Greece , Turkey ... systems at the core of life science research. , ... ... ...
... patient cases using magnetic resonance-guided heat (laser interstitial ... cancer recurrence after surgical removal of the prostate ... of Interventional Radiology,s 35th Annual Scientific Meeting in ... salvage radiation treatment and are often presented with ...
Cached Biology Technology:Zimmer Holdings to Present at Barclays Capital 2010 Global Healthcare Conference 2Ingenuity Systems Announces New Distributor for Greece, Turkey and the Balkans 2Ingenuity Systems Announces New Distributor for Greece, Turkey and the Balkans 3The hot -- and cold -- interventional radiology treatments for recurrent prostate cancer 2The hot -- and cold -- interventional radiology treatments for recurrent prostate cancer 3
(Date:11/4/2014)... marketing directed at children on the interior and ... the majority of black, middle-income and rural communities ... Authored by Arizona State University researcher Punam Ohri-Vachaspati ... to examine the use of child-directed marketing on ... and its relationship to demographics. It adds to ...
(Date:11/4/2014)... – (Nov. 4, 2014) – A majority of Madagascar,s ... that could have serious consequences for the rainforests they ... shows the positive impacts lemurs can have on rainforest ... their disappearance could have on the region,s rich biodiversity. ... have fruits eaten by lemurs. Lemurs in turn ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and Markets ... "Cell Therapy - Technologies, Markets and Companies" to their ... therapy technologies and methods, which have already started to play ... cell transplantation is replacing the old fashioned bone marrow transplants. ... therapy is bound to become a part of medical practice. ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... to study addicted,smokers, a new drug that attaches ... implicated in nicotine addiction ,may help studies ... and schizophrenia.,Developed by UC Irvine Transdisciplinary Tobacco Use ... selective binding agent,that identifies specific areas of the ...
... may be precipitated by a "traffic jam" within neurons ... and structures in the cells, according to new studies ... models of Alzheimer's disease and in human brain samples ... breakdown in neurons that appears to prevent the normal ...
... Scientists at Joslin Diabetes Center have discovered one reason why ... developing type 2 diabetes later in life. In studies of ... pancreas's ability to later secrete enough insulin in response to ... don't have delivery of enough nutrients from the mother to ...
Cached Biology News:Drug That 'Tags' Decision-making Areas Of The Brain May Aid 2Neuronal 'traffic jam' marks early Alzheimer's disease 2Neuronal 'traffic jam' marks early Alzheimer's disease 3Neuronal 'traffic jam' marks early Alzheimer's disease 4Poor prenatal nutrition permanently damages function of insulin-producing cells in the pancreas 2Poor prenatal nutrition permanently damages function of insulin-producing cells in the pancreas 3Poor prenatal nutrition permanently damages function of insulin-producing cells in the pancreas 4
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... protein Vtg in plasma from juvenile or male ... endocrine disrupting chemicals (EDCs) with estrogenic effects in ... screening test for the estrogenic effects of EDCs ... is a double-antibody immunometric (sandwich) EIA for analyzing ...
... is a 17 amino acid synthetic peptide whose sequence is from ... to carboxy terminus): C - N(217) - Q - P ... A - T - P - N - Y - T ... be used for neutralization and control experiments with the polyclonal antibody ...
... for which no antibody exists? Having difficulty generating ... a variety of pharmaceutical, biotech and academic researchers ... technology and expertise in antibody generation to work ... RabMAb development technology , High affinity and high ...
Biology Products: